Cargando…

Sacubitril‐valsartan initiation in chronic heart failure patients impacts sleep apnea: the ENTRESTO‐SAS study

AIMS: Optimizing medical cardiac treatment for sleep apnoea (SA) in patients with chronic heart failure and reduced ejection fraction (HFrEF) is an expert Grade C recommendation based on six studies encompassing a total of 67 patients only. Whether sacubitril–valsartan (SV), a cornerstone of HFrEF m...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jaffuel, Dany, Nogue, Erika, Berdague, Philippe, Galinier, Michel, Fournier, Pauline, Dupuis, Marion, Georger, Frédéric, Cadars, Marie‐Pierre, Ricci, Jean‐Etienne, Plouvier, Nathalie, Picard, François, Puel, Vincent, Mallet, Jean‐Pierre, Suehs, Carey M., Molinari, Nicolas, Bourdin, Arnaud, Roubille, François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318447/ https://www.ncbi.nlm.nih.gov/pubmed/34102018 http://dx.doi.org/10.1002/ehf2.13455

Ejemplares similares

Impact of sacubitril–valsartan combination in patients with chronic heart failure and sleep apnoea syndrome: the ENTRESTO‐SAS study design
por: Jaffuel, Dany, et al.
Publicado: (2018)

Exploring the Food and Drug Administration’s review and approval of Entresto (sacubitril/valsartan)
por: Eadie, Ashley L., et al.
Publicado: (2021)

Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman
por: Faber, Eve S., et al.
Publicado: (2016)

Cooling down with Entresto. Can sacubitril/valsartan combination enhance browning more than coldness?
por: Nikolic, Marina, et al.
Publicado: (2022)

Dapagliflozin initiation in chronic heart failure patients improves central sleep apnoea
por: Jaffuel, Dany, et al.
Publicado: (2023)

Patterns of adaptive servo-ventilation settings in a real-life multicenter study: pay attention to volume!: Adaptive servo-ventilation settings in real-life conditions
por: Jaffuel, Dany, et al.
Publicado: (2020)

What is the remaining status of adaptive servo-ventilation? The results of a real-life multicenter study (OTRLASV-study): Adaptive servo-ventilation in real-life conditions
por: Jaffuel, Dany, et al.
Publicado: (2019)

A prospective, randomized, double‐blind, placebo‐controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease
por: Newhard, Daniel K., et al.
Publicado: (2018)

Is the 2013 American Thoracic Society CPAP-tracking system algorithm useful for managing non-adherence in long-term CPAP-treated patients?
por: Rotty, Marie-Caroline, et al.
Publicado: (2019)

Sacubitril/Valsartan Conundrum
por: Somberg, John
Publicado: (2021)

Mask side-effects in long-term CPAP-patients impact adherence and sleepiness: the InterfaceVent real-life study
por: Rotty, Marie-Caroline, et al.
Publicado: (2021)

Did COVID-19 impact Positive Airway Pressure adherence in 2020? A cross-sectional study of 8477 patients with sleep apnea
por: Bertelli, Fanny, et al.
Publicado: (2022)

Apnoea–hypopnoea indices determined via continuous positive airway pressure (AHI-CPAP(flow)) versus those determined by polysomnography (AHI-PSG(gold)): a protocol for a systematic review and meta-analysis
por: Bertelli, Fanny, et al.
Publicado: (2021)

The Role of NF-κB and Bax/Bcl-2/Caspase-3 Signaling Pathways in the Protective Effects of Sacubitril/Valsartan (Entresto) against HFD/STZ-Induced Diabetic Kidney Disease
por: Mohany, Mohamed, et al.
Publicado: (2022)

Implication of low dose sacubitril/valsartan
por: Imamura, Teruhiko
Publicado: (2021)

Eligibility and Usage of Sacubitril/Valsartan in Korea
por: Kim, Jin-Jin, et al.
Publicado: (2019)

Is Entresto good for the brain?
por: Patel, Nirav, et al.
Publicado: (2017)

In ®Entresto we trust
por: Camilli, Massimiliano, et al.
Publicado: (2020)

Management of sleep apnoea syndrome (SAS) in patients with vasovagal syncope (VVS): a protocol for the VVS-SAS cohort study
por: Puel, Vincent, et al.
Publicado: (2020)

Insights into implementation of sacubitril/valsartan into clinical practice
por: Martens, Pieter, et al.
Publicado: (2018)

Sacubitril–valsartan in heart failure and multimorbidity patients
por: Rodil Fraile, Raquel, et al.
Publicado: (2018)

Re: Implication of low‐dose sacubitril/valsartan
por: Pandey, Amitabh C., et al.
Publicado: (2021)

Molecular mechanisms of sacubitril/valsartan in cardiac remodeling
por: Mustafa, Nor Hidayah, et al.
Publicado: (2022)

Effects of Sacubitril/Valsartan on the Renal Resistance Index
por: Gioia, Margherita Ilaria, et al.
Publicado: (2022)

Effect of sacubitril/valsartan or valsartan on ventricular remodeling and myocardial fibrosis in perimenopausal women with hypertension
por: Chen, Jianshu, et al.
Publicado: (2023)

Sacubitril/valsartan: evaluation of safety and efficacy as an antihypertensive treatment
por: Anderson, Sarah L, et al.
Publicado: (2018)

The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
por: Beck-da-Silva, Luís, et al.
Publicado: (2019)

Practical guidance on the use of sacubitril/valsartan for heart failure
por: Sauer, Andrew J., et al.
Publicado: (2018)

Sacubitril/valsartan increases postprandial gastrin and cholecystokinin in plasma
por: Andersen, Ulrik Ø, et al.
Publicado: (2020)

Effectiveness of sacubitril–valsartan in cancer patients with heart failure
por: Martín‐Garcia, Ana, et al.
Publicado: (2020)

Renin profiling predicts neurohormonal response to sacubitril/valsartan
por: Vergaro, Giuseppe, et al.
Publicado: (2020)

Sacubitril/valsartan in the treatment of systemic right ventricular failure
por: Zandstra, Tjitske E, et al.
Publicado: (2021)

Haemodynamic effects of sacubitril/valsartan in advanced heart failure
por: Gentile, Piero, et al.
Publicado: (2022)

A narrative review on sacubitril/valsartan and ventricular arrhythmias
por: Wei, Zhaoyang, et al.
Publicado: (2022)

Effects of sacubitril-valsartan in patients undergoing maintenance dialysis
por: Ding, Ying, et al.
Publicado: (2023)

Effect of sacubitril/valsartan on investigator‐reported ventricular arrhythmias in PARADIGM‐HF
por: Curtain, James P., et al.
Publicado: (2022)

Sacubitril/valsartan: A novel angiotensin receptor-neprilysin inhibitor
por: Dargad, Ramesh R., et al.
Publicado: (2018)

Valsartan/Sacubitril in heart failure and hypotension: how, when and why
por: Scardovi, Angela Beatrice, et al.
Publicado: (2019)

Reply: Sacubitril/valsartan for Chagas' heart disease heart failure?
por: Bocchi, Edimar Alcides, et al.
Publicado: (2018)

A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
por: Rawla, Prashanth, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_la23pap0sqb6as2qo2r78vo9ko